Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger’s Disease

Overview

The purpose of this expanded access program (EAP) is to provide Selexipag (Uptravi) for the treatment of participant with non-healing wound, buerger's disease.

Full Title of Study: “Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger’s Disease”

Study Type

  • Study Type: Expanded Access

Interventions

  • Drug: Selexipag

Investigator Details

  • Lead Sponsor
    • Actelion
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Actelion Clinical Trial, Study Director, Actelion
  • Overall Contact(s)
    • Contact, 1-800-JANSSEN (1-800-526-7736), Janssenmedinfo@its.jnj.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.